反应详情

To a stirred solution of crude (3-{3-[6-(2-morpholin-4-yl-ethylamino)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-phenylamino}-3-phenyl-propyl)-carbamic acid tert-butyl ester (329 mg, crude) in dichloromethane (1.5 mL) was added TFA (1.5 mL) at room temperature. The resulting mixture was stirred for 2 hours at room temperature. The reaction solution was concentrated under reduced pressure and partitioned between saturated NaHCO3 solution and ethyl acetate. The water phase was extracted with ethyl acetate again. The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography (silica gel, MeOH:dichloromethane, 1:100 to 1:10). The obtained solid was dissolved in a solution of HCl in MeOH and concentrated to give N1-{3-[6-(2-morpholin-4-yl-ethylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-phenyl}-1-phenyl-propane-1,3-diamine; hydrochloride. (Yield 20 mg).

1. concentrationThe reaction solution was concentrated under reduced pressure
2. custompartitioned between saturated NaHCO3 solution and ethyl acetate
3. extractionThe water phase was extracted with ethyl acetate again
4. dry with materialThe combined organic phase was dried over anhydrous Na2SO4
5. filtrationfiltered
6. concentrationconcentrated
7. customThe residue was purified by column chromatography (silica gel, MeOH:dichloromethane, 1:100 to 1:10)
8. dissolutionThe obtained solid was dissolved in a solution of HCl in MeOH
9. concentrationconcentrated